Through its AbSieve technology AbCheck can combine the strengths of two leading display concepts in our industry, namely phage-display and yeast display. AbSieve is AbCheck’s next-generation yeast display and antibody selection process including the upstream enrichment of target-specific candidates and batch cloning into yeast-display vectors. AbSieve, combined with our affinity maturation and lead optimization technology, AbAccel, speeds up drug discovery by high throughput screens in the final drug format and delivers antibodies for therapeutic application with high affinity and stability.

Yeast display has given drug developers the possibility to screen in the final drug format and use FACS screening systems to select promising therapeutic candidates easily and fast with no bacterial transfection and incubation times needed. This has however come at the costs of the inablity of classical yeast display approaches to generate as diverse libraries as the phage-display platform has to offer. AbCheck’s approach can truly offer the best of both worlds.
  Imprint Disclaimer